Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

BACKGROUND/AIM: Presently, there are no therapeutic options for unresectable hepatocellular carcinoma (u‐HCC) patients who are intolerant to sorafenib or regorafenib failure. There have been no reports with detailed clinical findings of lenvatinib (LEN), a newly developed first‐line tyrosine kinase...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Atsukawa, Masanori, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Shibata, Hiroshi, Ishikawa, Toru, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Itokawa, Norio, Imai, Michitaka, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6346240/
https://ncbi.nlm.nih.gov/pubmed/30575325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1909
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars